Open

Solid Tumors Treatment Study

In this study, we aim to improve treatment for advanced solid tumors. We are exploring how safe and effective valemetostat tosylate is when used together with DXd ADC.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

You will receive the study drug as a pill or infusion. You will asked to come to clinical in 15 day intervals to receive drug and have your vitals taken. This will continue until disease progression or other reason for discontinuation.

Incentives

Study Drug

In-person visits:
All

Total length of participation:
Until disease progression

Looking for Specific Volunteers

Able to participate:

You have a solid tumor type cancer
You are willing to donate tumor tissue from either a new biopsy or from a previous biopsy if tissue is available.

Not eligible if:

You have a serious heart condition
You have a serious lung condition
You have an active infection wtih: HIC, Hepatitis B or C
You are pregnant, breastfeeding, or intend to become pregnant during the study

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clincal Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Claire Dees
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Phase 1 Trials (all cancers))

IRB Number

24-0877

ClinicalTrials.gov

NCT06244485

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.